Wendell Wierenga

Wendell Wierenga

Vorsitzender bei CRINETICS PHARMACEUTICALS, INC.

Vermögen: 6 Mio $ am 31.05.2024

76 Jahre
Health Technology
Consumer Services
Commercial Services

Profil

Wendell D.
Wierenga
is currently serving as the Chairman at Crinetics Pharmaceuticals, Inc. since 2015.
He is also an Independent Director at Cytokinetics, Inc. since 2011 and an Independent Director at Dermata Therapeutics, Inc. since 2016.
In his former positions, Dr. Wierenga served as the Chief Executive Officer at Syrrx, Inc. from 2000 to 2003.
He held the position of Executive Director-Discovery Research at Pharmacia & Upjohn, Inc. He also served as the Executive Director-Discovery Research at The Upjohn Co. from 1974 to 1990.
Dr. Wierenga was an Independent Director at Onyx Pharmaceuticals, Inc. from 1996 to 2013.
He served as an Independent Director at Apricus Biosciences, Inc. from 2014 to 2019.
Additionally, he held the position of Director at Aspira Women's Health, Inc., Concert Pharmaceuticals, Inc., Patara Pharma LLC, and SRI International.
Dr. Wierenga was an Independent Director at XenoPort, Inc. from 2000 to 2016.
He served as an Independent Director at OCERA Therapeutics LLC from 2013 to 2017 and at Anacor Pharmaceuticals LLC from 2014 to 2016.
He was the Vice President-Medtech Ventures at Warner-Lambert Co. from 1992 to 2000.
Dr. Wierenga also served as the Executive Vice President-Research & Development at Neurocrine Biosciences, Inc. from 2003 to 2006, at Santarus, Inc. from 2011 to 2014, and at Ambit Biosciences Corp.
from 2007 to 2011.
He held the position of Senior Vice President-Research at Parke-Davis Pharmaceutical Research, Inc. from 1990 to 2000.
He was also the Senior VP-Worldwide Pharmaceutical Sciences at Pfizer Inc. from 1990 to 2000.
Dr. Wierenga obtained a doctorate degree from Stanford University and an undergraduate degree from Hope College.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
07.06.2024 109 246 ( 0,14% ) 5 Mio $ 31.05.2024
15.05.2024 24 327 ( 0,02% ) 1 Mio $ 31.05.2024
20.03.2024 260 ( 0,06% ) 997 $ 31.05.2024

Aktive Positionen von Wendell Wierenga

UnternehmenPositionBeginn
CYTOKINETICS, INCORPORATED Direktor/Vorstandsmitglied 09.02.2011
CRINETICS PHARMACEUTICALS, INC. Vorsitzender 01.10.2015
DERMATA THERAPEUTICS, INC. Direktor/Vorstandsmitglied 20.09.2016
Alle aktiven Positionen von Wendell Wierenga

Ehemalige bekannte Positionen von Wendell Wierenga

UnternehmenPositionEnde
Direktor/Vorstandsmitglied 24.01.2019
Direktor/Vorstandsmitglied 01.11.2018
OCERA THERAPEUTICS INC Direktor/Vorstandsmitglied 11.12.2017
XENOPORT, INC. Direktor/Vorstandsmitglied 01.08.2016
ANACOR PHARMACEUTICALS INC Direktor/Vorstandsmitglied 24.06.2016
Sehen Sie sich die Erfahrung von Wendell Wierenga im Detail an

Ausbildung von Wendell Wierenga

Hope College Undergraduate Degree
Stanford University Doctorate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Wendell Wierenga im Detail an

Beziehungen

100 +

Beziehungen ersten Grades

23

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen6
NEUROCRINE BIOSCIENCES, INC.

Health Technology

ASPIRA WOMEN'S HEALTH INC.

Health Technology

PFIZER, INC.

Health Technology

CYTOKINETICS, INCORPORATED

Health Technology

CRINETICS PHARMACEUTICALS, INC.

Health Technology

DERMATA THERAPEUTICS, INC.

Health Technology

Private Unternehmen15

Health Technology

Health Technology

Health Technology

Health Technology

Pharmacia & Upjohn, Inc.

Health Technology

The Upjohn Co.

Health Technology

Health Technology

Parke-Davis Pharmaceutical Research, Inc.

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Sehen Sie sich die Unternehmensverbindungen an
  1. Börse
  2. Insiders
  3. Wendell Wierenga
-40 % Zeitlich begrenztes Angebot: Unsere Abonnements führen Sie zu den besten Investitionen von morgen.
PROFITIEREN SIE JETZT